ERBB2 and breast carcinoma: Additionally, a combination of HDACI entinostat and Her2/EGF-receptor kinase inhibitor, lapatinib synergistically inhibited Akt signaling to promote apoptosis in HER2-overexpressing breast cancer cells [106].